



For settlement questions, or to get the claim process started, contact
Janice Hart at (800) 729-5998 or email
jhart@nationalequity.com

Zetia Antitrust Settlement

In re Zetia (Ezetimibe) Antitrust Litigation, Civil Action No. 2:18-md-2836



Funds Amount: TBD

Purchase Dates: November 15, 2015 –
November 19, 2019

Filing Deadline: TBD

ELIGIBILITY:

All Third-Party Payor entities (“TPPs”) within the Brand Subclass or the Generic Subclass that, for consumption by their members, employees, insureds, participants, or beneficiaries, and not for resale, indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of Zetia or its AB-rated generic equivalents in any form, in AL, AZ, CA, DC, FL, HI, IL, IA, KS, ME, MI, MN, MS, NE, NV, NH, NM, NY, NC, ND, OR, PR, RI, SD, TN, UT, VT, VA, WV and WI from November 15, 2014 through November 18, 2019. Cities, Towns, and Municipalities with self-funded prescription drug plans are eligible for this settlement.

SUMMARY:

Plaintiffs allege that Defendants violated state antitrust, consumer protection, and unjust enrichment laws by allegedly participating in an unlawful scheme to delay and impede the market entry of less expensive, generic versions of Zetia. Specifically, Plaintiffs allege that the Merck Defendants entered into unlawful non-competition agreements with the Glenmark Defendants, whereby the Merck Defendants agreed to pay the Glenmark Defendants in exchange for the Glenmark Defendants agreeing to delay selling their generic version of Zetia. Plaintiffs allege that they and other members of the Class were injured by being overcharged on their Zetia branded and generic purchases during the class period resulting from Defendants’ alleged anticompetitive conduct. Plaintiffs seek to recover monetary damages for those overcharges.